MCID: ADN015
MIFTS: 34

Adenoid Basal Cell Carcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases

Aliases & Classifications for Adenoid Basal Cell Carcinoma

Aliases & Descriptions for Adenoid Basal Cell Carcinoma:

Name: Adenoid Basal Cell Carcinoma 12 14
Skin Adenoid Basal Cell Carcinoma 12
Basal Cell Carcinoma - Adenoid 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4294

Summaries for Adenoid Basal Cell Carcinoma

MalaCards based summary : Adenoid Basal Cell Carcinoma, also known as skin adenoid basal cell carcinoma, is related to adenoiditis and basal cell carcinoma. An important gene associated with Adenoid Basal Cell Carcinoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are Cell cycle Role of SCF complex in cell cycle regulation and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Fluconazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include skin and salivary gland, and related phenotypes are endocrine/exocrine gland and integument

Related Diseases for Adenoid Basal Cell Carcinoma

Diseases related to Adenoid Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
id Related Disease Score Top Affiliating Genes
1 adenoiditis 10.3
2 basal cell carcinoma 10.3
3 marfanoid hypermobility syndrome 10.3 KIT PGR
4 skin angiosarcoma 10.3 KIT PGR
5 liver angiosarcoma 10.3 KIT PGR
6 uterine hypoplasia 10.3 KIT PGR
7 intestinal neuroendocrine benign tumor 10.3 KIT PGR
8 acute disseminated encephalomyelitis 10.3 CDKN2A KIT
9 pericardium leiomyoma 10.3 CDKN2A PGR
10 pleuropneumonia 10.2 CDKN2A PGR
11 bartholin's gland benign neoplasm 10.2 ESR1 PGR
12 cardiovascular organ benign neoplasm 10.2 ESR1 PGR
13 appendix leiomyoma 10.2 ESR1 PGR
14 bronchus adenoma 10.2 ESR1 PGR
15 glioma 10.2 ESR1 PGR
16 sebaceous adenoma 10.2 KIT PGR
17 vulval paget's disease 10.2 CDKN2A KIT
18 ovarian benign neoplasm 10.2 ESR1 PGR
19 ovarian embryonal carcinoma 10.2 KIT PGR
20 plexiform neurofibroma 10.2 ESR1 PGR
21 paranasal sinus disease 10.2 ESR1 PGR
22 fragile x-associated tremor/ataxia syndrome 10.2 CDKN2A KIT
23 deafness, autosomal recessive 21 10.2 ESR1 PGR
24 acantholytic acanthoma 10.2 B2M PGR
25 nonossifying fibromyxoid tumor 10.2 KIT KRT7
26 cervical lymphoepithelioma-like carcinoma 10.2 ESR1 PGR
27 histiocytic and dendritic cell cancer 10.2 ESR1 PGR
28 pediatric intraocular retinoblastoma 10.2 ESR1 PGR
29 congenital disorder of glycosylation, type ic 10.2 ESR1 PGR
30 her2-receptor negative breast cancer 10.2 ESR1 PGR
31 intestinal perforation 10.2 ESR1 PGR
32 perlman syndrome 10.2 ESR1 PGR
33 osteogenesis imperfecta 10.2 ESR1 PGR
34 poliomyelitis 10.2 ESR1 PGR
35 precursor lymphoblastic lymphoma/leukemia 10.2 KRT7 PGR
36 villoglandular endometrial endometrioid adenocarcinoma 10.2 ESR1 PGR
37 vaginal adenosarcoma 10.2 ESR1 PGR
38 intraneural perineurioma 10.2 ESR1 PGR
39 subareolar duct papillomatosis 10.2 CDKN2A ESR1
40 gallbladder pleomorphic giant cell adenocarcinoma 10.2 B2M CDKN2A
41 adult epithelioid sarcoma 10.2 B2M CDKN2A
42 central nervous system mature teratoma 10.2 ESR1 PGR
43 suppurative lymphadenitis 10.2 CDKN2A KRT7
44 biemond syndrome 10.2 KRT7 PGR
45 acute thyroiditis 10.2 ESR1 PGR
46 mesenchymoma 10.2 KIT PGR
47 denture stomatitis 10.2 B2M TNC
48 tibial nerve palsy 10.2 B2M TNC
49 postpoliomyelitis syndrome 10.2 CDKN2A KRT7
50 bowman's membrane folds or rupture 10.2 KRT7 PGR

Graphical network of the top 20 diseases related to Adenoid Basal Cell Carcinoma:



Diseases related to Adenoid Basal Cell Carcinoma

Symptoms & Phenotypes for Adenoid Basal Cell Carcinoma

MGI Mouse Phenotypes related to Adenoid Basal Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.73 B2M CDKN2A ESR1 KIT LALBA PGR
2 integument MP:0010771 9.63 B2M CDKN2A ESR1 KIT LALBA PGR
3 neoplasm MP:0002006 9.43 PGR SPN B2M CDKN2A ESR1 KIT
4 no phenotypic analysis MP:0003012 9.02 CDKN2A ESR1 KIT PGR TNC

Drugs & Therapeutics for Adenoid Basal Cell Carcinoma

Drugs for Adenoid Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
2
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
3
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
4
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
7
Doxepin Approved Phase 3 1668-19-5 667477 667468
8
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
9 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
10 Anti-Infective Agents Phase 2, Phase 3,Phase 1
11 Liver Extracts Phase 3,Phase 2,Phase 1
12
Megestrol Phase 3 3562-63-8 19090 3080587
13 pancreatic polypeptide Phase 3
14 Analgesics Phase 3
15 Cholinergic Agents Phase 3
16 Adjuvants, Anesthesia Phase 3
17 Narcotics Phase 3
18 Neurotransmitter Agents Phase 3
19 Steroid Synthesis Inhibitors Phase 2, Phase 3
20 Contraceptive Agents Phase 3
21 Contraceptives, Oral Phase 3
22 Cytochrome P-450 CYP2C9 Inhibitors Phase 2, Phase 3
23 Analgesics, Opioid Phase 3
24 Hormone Antagonists Phase 2, Phase 3
25 Anesthetics Phase 3
26 Hormones Phase 2, Phase 3,Phase 1
27 Anesthetics, General Phase 3
28 Anesthetics, Intravenous Phase 3
29 Peripheral Nervous System Agents Phase 3
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
31 Antifungal Agents Phase 2, Phase 3,Phase 1
32 Antimitotic Agents Phase 3,Phase 2,Phase 1
33 Appetite Stimulants Phase 3
34 Autonomic Agents Phase 3
35 Antineoplastic Agents, Hormonal Phase 3
36 Central Nervous System Depressants Phase 3
37 Central Nervous System Stimulants Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39 Histamine Antagonists Phase 3
40 Antidepressive Agents Phase 3
41 Antidepressive Agents, Tricyclic Phase 3
42 Psychotropic Drugs Phase 3
43 Cola Nutraceutical Phase 3,Phase 2,Phase 1
44
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
45
Indinavir Approved Phase 2 150378-17-9 5362440
46
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
47
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
48
Etoposide Approved Phase 2 33419-42-0 36462
49
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
50
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904

Interventional clinical trials:

(show top 50) (show all 61)
id Name Status NCT ID Phase
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
2 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
3 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
4 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
5 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3
6 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Active, not recruiting NCT01156142 Phase 3
7 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3
8 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Unknown status NCT00003489 Phase 2
9 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
10 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2
11 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
12 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
13 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
14 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2
15 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2
16 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2
17 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2
18 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2
19 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2
20 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Recruiting NCT01806675 Phase 1, Phase 2
21 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Not yet recruiting NCT02978625 Phase 2
22 MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer Unknown status NCT00984074 Phase 1
23 Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00023959 Phase 1
24 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1
25 Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Completed NCT01637194 Phase 1
26 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Completed NCT00397384 Phase 1
27 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
28 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
29 Head & Neck Cancer Survivorship: Physical and Functional Status Completed NCT00751816 Phase 1
30 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1
31 Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors Completed NCT00010023 Phase 1
32 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1
33 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
34 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1
35 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1
36 Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer Completed NCT00019110 Phase 1
37 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
38 NGR-TNF in Treating Patients With Advanced Solid Tumors Completed NCT00098943 Phase 1
39 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
40 Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer Active, not recruiting NCT00470496 Phase 1
41 Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer Active, not recruiting NCT00851253 Phase 1
42 Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin Terminated NCT00023790 Phase 1
43 S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors Withdrawn NCT00937417 Phase 1
44 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733
45 Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Completed NCT00068497
46 L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer Completed NCT01155609
47 Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer Completed NCT00897793
48 Family Quality of Life Among Families With a Member Who is a Cancer Patient Completed NCT00544336
49 Immunoreactivity to Cetuximab in Cancer Patients Completed NCT00896896
50 Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00973947

Search NIH Clinical Center for Adenoid Basal Cell Carcinoma

Genetic Tests for Adenoid Basal Cell Carcinoma

Anatomical Context for Adenoid Basal Cell Carcinoma

MalaCards organs/tissues related to Adenoid Basal Cell Carcinoma:

39
Skin, Salivary Gland

Publications for Adenoid Basal Cell Carcinoma

Articles related to Adenoid Basal Cell Carcinoma:

id Title Authors Year
1
Adenoid basal cell carcinoma: a rare facet of basal cell carcinoma. ( 27095806 )
2016
2
Coexistence of Solid (Nodular) and Differentiated (Adenoid) Basal Cell Carcinoma at the Same Anatomical Site. ( 26538745 )
2015
3
CD117 and CD43 are useful adjuncts in the distinction of adenoid cystic carcinoma from adenoid basal cell carcinoma. ( 25551301 )
2015
4
Adenoid basal cell carcinoma and its mimics. ( 23723508 )
2013
5
Adenoid Basal cell carcinoma simulating ameloblastoma. ( 19549180 )
2009
6
A Case of Axillary Adenoid Basal Cell Carcinoma. ( 27303153 )
2008
7
Tenascin expression in adenoid basal cell carcinoma of the skin. ( 8615597 )
1996
8
Giant adenoid basal cell carcinoma. ( 8060083 )
1994
9
Primary adenoid cystic carcinoma of the skin. A clinical, histological, and immunocytochemical comparison with adenoid cystic carcinoma of salivary glands and adenoid basal cell carcinoma. ( 3010759 )
1986
10
Adenoid basal cell carcinoma of the vulva. ( 7185765 )
1982

Variations for Adenoid Basal Cell Carcinoma

Cosmic variations for Adenoid Basal Cell Carcinoma:

9 (show top 50) (show all 223)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM44130 TP53 skin,NS,carcinoma,basal cell carcinoma c.477C>T p.A159A 9
2 COSM43920 TP53 skin,NS,carcinoma,basal cell carcinoma c.680C>T p.S227F 9
3 COSM10705 TP53 skin,NS,carcinoma,basal cell carcinoma c.586C>T p.R196* 9
4 COSM10654 TP53 skin,NS,carcinoma,basal cell carcinoma c.637C>T p.R213* 9
5 COSM45774 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 9
6 COSM11084 TP53 skin,NS,carcinoma,basal cell carcinoma c.517G>A p.V173M 9
7 COSM10662 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>A p.R248Q 9
8 COSM44097 TP53 skin,NS,carcinoma,basal cell carcinoma c.530C>T p.P177L 9
9 COSM44603 TP53 skin,NS,carcinoma,basal cell carcinoma c.835G>A p.G279R 9
10 COSM45424 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 9
11 COSM44435 TP53 skin,NS,carcinoma,basal cell carcinoma c.96+1G>A p.? 9
12 COSM10659 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 9
13 COSM10728 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 9
14 COSM43837 TP53 skin,NS,carcinoma,basal cell carcinoma c.843C>G p.D281E 9
15 COSM10749 TP53 skin,NS,carcinoma,basal cell carcinoma c.830G>T p.C277F 9
16 COSM45322 TP53 skin,NS,carcinoma,basal cell carcinoma c.757A>G p.T253A 9
17 COSM10995 TP53 skin,NS,carcinoma,basal cell carcinoma c.580C>T p.L194F 9
18 COSM43582 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 9
19 COSM10656 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 9
20 COSM10650 TP53 skin,NS,carcinoma,basal cell carcinoma c.529C>T p.P177S 9
21 COSM11152 TP53 skin,NS,carcinoma,basal cell carcinoma c.700T>C p.Y234H 9
22 COSM10726 TP53 skin,NS,carcinoma,basal cell carcinoma c.856G>A p.E286K 9
23 COSM10794 TP53 skin,NS,carcinoma,basal cell carcinoma c.796G>A p.G266R 9
24 COSM10939 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 9
25 COSM10648 TP53 skin,NS,carcinoma,basal cell carcinoma c.524G>A p.R175H 9
26 COSM45304 TP53 skin,NS,carcinoma,basal cell carcinoma c.375+1G>A p.? 9
27 COSM44398 TP53 skin,NS,carcinoma,basal cell carcinoma c.682G>A p.D228N 9
28 COSM44606 TP53 skin,NS,carcinoma,basal cell carcinoma c.665C>T p.P222L 9
29 COSM44310 TP53 skin,NS,carcinoma,basal cell carcinoma c.738G>A p.M246I 9
30 COSM11376 TP53 skin,NS,carcinoma,basal cell carcinoma c.737T>G p.M246R 9
31 COSM10867 TP53 skin,NS,carcinoma,basal cell carcinoma c.797G>A p.G266E 9
32 COSM10812 TP53 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.S241F 9
33 COSM10704 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 9
34 COSM43842 TP53 skin,NS,carcinoma,basal cell carcinoma c.770T>C p.L257P 9
35 COSM6549 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>T p.R248L 9
36 COSM45733 TP53 skin,NS,carcinoma,basal cell carcinoma c.432G>A p.Q144Q 9
37 COSM6932 TP53 skin,NS,carcinoma,basal cell carcinoma c.733G>A p.G245S 9
38 COSM44226 TP53 skin,NS,carcinoma,basal cell carcinoma c.380C>T p.S127F 9
39 COSM10768 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 9
40 COSM10905 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 9
41 COSM43714 TP53 skin,NS,carcinoma,basal cell carcinoma c.836G>A p.G279E 9
42 COSM43583 TP53 skin,NS,carcinoma,basal cell carcinoma c.425C>T p.P142L 9
43 COSM10863 TP53 skin,NS,carcinoma,basal cell carcinoma c.833C>T p.P278L 9
44 COSM11449 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 9
45 COSM43700 TP53 skin,NS,carcinoma,basal cell carcinoma c.712T>A p.C238S 9
46 COSM45751 TP53 skin,NS,carcinoma,basal cell carcinoma c.511G>C p.E171Q 9
47 COSM44126 TP53 skin,NS,carcinoma,basal cell carcinoma c.507G>A p.M169I 9
48 COSM45074 TP53 skin,NS,carcinoma,basal cell carcinoma c.829T>G p.C277G 9
49 COSM10988 TP53 skin,NS,carcinoma,basal cell carcinoma c.772G>A p.E258K 9
50 COSM45732 TP53 skin,NS,carcinoma,basal cell carcinoma c.480G>C p.M160I 9

Expression for Adenoid Basal Cell Carcinoma

Search GEO for disease gene expression data for Adenoid Basal Cell Carcinoma.

Pathways for Adenoid Basal Cell Carcinoma

GO Terms for Adenoid Basal Cell Carcinoma

Biological processes related to Adenoid Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 stem cell differentiation GO:0048863 9.16 ESR1 KIT
2 somatic stem cell division GO:0048103 8.96 CDKN2A KIT
3 positive regulation of phospholipase C activity GO:0010863 8.62 ESR1 KIT

Molecular functions related to Adenoid Basal Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 8.62 ESR1 PGR

Sources for Adenoid Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....